Ovid Therapeutics (OVID) Non-Current Debt (2019 - 2020)
Ovid Therapeutics' (OVID) quarterly Non-Current Debt came in at $61200.0 in Q4 2020, down 78.64% on a YoY basis from $286562.0 in Q1 2020, and little changed quarter-over-quarter from $61200.0 in Q3 2020.
Powered by 
Analysis
Ovid Therapeutics (OVID) Non-Current Debt (2019 - 2020) Analysis & Trends
Ovid Therapeutics (OVID) has reported Non-Current Debt for 2 consecutive years, with $61200.0 the latest figure, recorded in Q4 2020.
- For the quarter ending Q4 2020, Non-Current Debt fell 78.64% year-over-year to $61200.0; the trailing twelve-month figure through Dec 2020 stood at $61200.0 (down 78.64% YoY), and the FY2020 full-year result was $61200.0, down 78.64% from the prior year.
- Non-Current Debt held at $61200.0 in Q4 2020 per OVID's latest filing, from $61200.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.3 million in Q1 2019 and bottomed at $61200.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 60.50 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 17.02 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 882.16 Mn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 61,200.00 |
| Sep 30, 2020 | 61,200.00 |
| Jun 30, 2020 | 286,562.00 |
| Mar 31, 2020 | 286,562.00 |
| Dec 31, 2019 | 286,562.00 |
| Sep 30, 2019 | 286,562.00 |
| Jun 30, 2019 | 286,562.00 |
| Mar 31, 2019 | 1.34 Mn |